Illumina (NASDAQ:ILMN) was upgraded by analysts at Citigroup from a “neutral” rating to a “buy” rating in a report released on Monday, MarketBeat.com reports. The firm currently has a $275.00 target price on the life sciences company’s stock, up from their previous target price of $260.00. Citigroup’s price target indicates a potential upside of 29.11% from the company’s current price.
Other analysts have also recently issued reports about the company. Piper Jaffray Companies restated an “overweight” rating and set a $226.00 price target (up from $202.00) on shares of Illumina in a report on Monday, October 9th. Canaccord Genuity restated a “buy” rating and set a $230.00 price target (up from $215.00) on shares of Illumina in a report on Thursday, October 12th. Deutsche Bank upgraded Illumina from a “hold” rating to a “buy” rating and reduced their price target for the stock from $195.00 to $160.00 in a report on Monday, October 23rd. Janney Montgomery Scott upgraded Illumina from a “sell” rating to a “neutral” rating in a report on Monday, October 23rd. Finally, Robert W. Baird upgraded Illumina from a “neutral” rating to an “outperform” rating and boosted their price target for the stock from $184.00 to $228.00 in a report on Wednesday, October 25th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $241.39.
Illumina (NASDAQ:ILMN) traded down $7.18 during trading on Monday, reaching $213.00. The company’s stock had a trading volume of 1,453,462 shares, compared to its average volume of 931,511. Illumina has a 1 year low of $158.02 and a 1 year high of $248.97. The company has a debt-to-equity ratio of 0.42, a quick ratio of 3.55 and a current ratio of 3.99. The company has a market capitalization of $31,100.00, a PE ratio of 43.20, a PEG ratio of 2.91 and a beta of 0.92.
Illumina (NASDAQ:ILMN) last released its earnings results on Tuesday, January 30th. The life sciences company reported $1.44 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.22 by $0.22. Illumina had a return on equity of 21.52% and a net margin of 26.56%. The firm had revenue of $778.00 million for the quarter, compared to analysts’ expectations of $752.04 million. During the same quarter in the previous year, the business posted $0.85 earnings per share. The business’s revenue for the quarter was up 25.7% on a year-over-year basis. research analysts forecast that Illumina will post 4.59 earnings per share for the current year.
In related news, Director Jay T. Flatley sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 7th. The stock was sold at an average price of $210.59, for a total value of $4,211,800.00. Following the sale, the director now directly owns 536,717 shares in the company, valued at $113,027,233.03. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Marc Stapley sold 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $205.48, for a total value of $410,960.00. Following the completion of the sale, the executive vice president now owns 30,370 shares in the company, valued at $6,240,427.60. The disclosure for this sale can be found here. Insiders sold 136,922 shares of company stock worth $30,023,609 over the last quarter. 0.89% of the stock is currently owned by company insiders.
Hedge funds have recently made changes to their positions in the stock. SeaCrest Wealth Management LLC bought a new stake in Illumina in the fourth quarter valued at approximately $154,000. Dupont Capital Management Corp acquired a new position in Illumina in the third quarter valued at approximately $153,000. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its stake in Illumina by 113.9% in the fourth quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 770 shares of the life sciences company’s stock valued at $168,000 after buying an additional 410 shares during the period. Advisory Services Network LLC lifted its stake in Illumina by 13.0% in the second quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock valued at $134,000 after buying an additional 89 shares during the period. Finally, Riverbridge Partners LLC acquired a new position in Illumina in the fourth quarter valued at approximately $202,000. Institutional investors and hedge funds own 92.09% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Illumina (ILMN) Rating Increased to Buy at Citigroup” was reported by American Banking News and is the property of of American Banking News. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/02/05/illumina-ilmn-rating-increased-to-buy-at-citigroup.html.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.